HRT Financial’s Madrigal Pharmaceuticals MDGL Stock Holding History

HRT Financial’s Portfolio MDGL Stock Details MDGL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$261K	Buy	+500	New	+$239K	﹤0.01%	2992

Other funds holding MDGL

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Paulson & Co New York $3.11B AUM 94.93% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

HRT Financial's MDGL Position: Q1 2026 in Review

HRT Financial sold out of Madrigal Pharmaceuticals (MDGL) in Q1 2026, closing a stake of 4,218 shares — an estimated $2.02M sold.

HRT Financial first reported a position in MDGL in Q3 2019 and held it in 10 quarters. The position peaked at $3.88M in Q4 2024. 378 funds tracked by Wall St. Rank hold MDGL as of Q1 2026.

HRT Financial reported no remaining Madrigal Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
HRT Financial sold 4,218 Madrigal Pharmaceuticals shares in Q1 2026, an estimated $2.02M.
HRT Financial first reported a position in Madrigal Pharmaceuticals in Q3 2019 and held it in 10 quarters.
HRT Financial's Madrigal Pharmaceuticals position peaked at $3.88M in Q4 2024.
378 funds tracked by Wall St. Rank held Madrigal Pharmaceuticals as of Q1 2026.

Based on HRT Financial's 13F filing for Q1 2026, filed 14 May 2026.